Plus   Neg

Stock Alert: Kratos Stock Sinks 14% On Q4 Results, Guidance

Shares of Kratos Defense & Security Solutions Inc. (KTOS) are currently losing 14% on Tuesday morning session after the defense company reported fourth-quarter results that fell short of Wall Street expectations. The company also provided first quarter revenue outlook, below the consensus estimates.

Fourth-quarter net income dropped to $3.0 million or $0.03 per share from $4.7 million or $0.04 per share last year. Adjusted earnings were reported at $0.09 per share. Kratos' revenues rose 12.6% to $185.1 million from $164.4 million last year.

Analysts polled by Thomson Reuters estimated earnings of $0.10 per share on revenues of $197.34 million for the quarter.

For the first quarter, Kratos expects revenues of $160 million to $170 million. Analysts estimate revenues of $190.54 million.

KTOS is currently trading at $16.68, down $2.63 or 13.62%, on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hyundai Motor has launched a new IONIQ brand dedicated to battery electric vehicles, as the automaker is accelerating its efforts to gain a share in the fast-growing global EV market. Under the IONIQ brand, Hyundai plans to introduce three new dedicated electric vehicle models over the next four years. Hyundai is South Korea's largest automaker. Amazon.com, Inc. is in talks with mall operator Simon Property Group, Inc. to use the abandoned anchor departmental stores of JC Penny and Sears at their malls as fulfillment centers, reports said. This is expected to help the e-commerce giant in boosting their last mile delivery, which is the last leg of the delivery process. The U.S. Food and Drug Administration announced the approval of Trevena Inc.'s Olinvyk (oliceridine), a new opioid for intravenous use in hospitals or other controlled clinical settings. Olinvyk is an opioid agonist to manage moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.
Follow RTT